This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

A synopsis of individual key papers that evidence improved patient outcomes and increased economic benefit with a TAVI procedure vs alternative pathways, taking into account organisational efficiency, budget considerations, patient choice and how to implement change in your organisation.

Annual Number of Candidates for TAVI Per Country: Current Estimates and Future Projections

 

Authors: Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, et al.

Citation: Eur Heart J. 2018 Jul 21;39(28):2635-2642.
doi: 10.1093/eurheartj/ehy107.

Period of study: January 2017

The Vancouver 3M Clinical Pathway Facilitates Safe Next-Day Discharge Home

 

Authors: Wood DA, Lauck SB, Cairns JA, Humphriees KH, et al.

Citation: JACC Cardiovasc Interv. 2019;12:459–68
DOI:10.1016/j.jcin.2018.12.0020.

Period of study: March 2015 and April 2017

Optimising patient discharge management after transfemoral TAVI: The European FAST-TAVI trial

 

Authors: Barbanti M, van Mourik MS, Spence MS, Iacovelli F, et al.

Citation: EuroIntervention. 2019;15:147–54
DOI:10.4244/EIJ-D-18-01197.

Patient enrolment: May 2015 – October 2017

Vancouver TAVR Clinical Pathway. Min. Approach, Standardized Care, and Discharge Criteria to Reduce LoS

 

Authors: Lauck SB, Wood DA, Baumbusch J, Kwon J-Y, et al.

Citation: Circ Cardiovasc Qual Outcomes. 2016;9:312–21. DOI:10.1161/CIRCOUTCOMES.115.002541.

Period of study: May 2012 to October 2014

Comparison of local versus general anesthesia in patients undergoing TAVR: A meta-analysis

 

Authors: Villablanca P.A, Mohananey D, Nikolic K, Bangalore S, et al.

Citation: Catheter Cardiovasc Interv. 2018;91:330–42
DOI: 10.1002/ccd.27207.

Period of study: Meta-analysis of studies 2008–2016

Length of stay after transfemoral TAVR: an analysis of the STS/ACC TVT Registry

 

Authors: Wayangankar SA, Elgendy IY, Xiang Q, Jneid H, et al.

Citation: JACC Cardiovasc Interv. 2019;12:422-430.
doi:0.1016/j.jcin.2018.11.015.

Period of study: November 2011 to September 2015

TAVR versus surgical valve replacement in intermediate-risk patients: A propensity score analysis

 

Authors: Thourani VH, Kodali S, Makkar RR, Hermann HC, et al.

Citation: Lancet. 2016;387:2218–25
DOI:10.1016/S0140-6736(16)30073-3.

Period of study: December 2011 – November 2013

Thirty-day readmission after TAVR in the United States: Insights from the Nationwide Readmission Database

 

Authors: Kolte D, Khere S, Sardar MR, Gheewala N, et al.

Citation: Circ Cardiovasc Interv. 2017;10:e004472
DOI:10.1161/CIRCINTERVENTIONS.116.00472.

Period of study: January to November 2013

Transcatheter Aortic-Valve Replacement with a Balloon Expandable Valve in Low-Risk Patients

 

Authors: Mack MJ, Leon MD, Thourani VH, Makkar R, et al. for the PARTNER 3 Investigators

Citation: N Engl J Med. 2019;380:1695–1705
DOI: 10.1056/NEJMoal1814052.

Period of study: March 2016 – October 2017

Health Status after Transcatheter vs Surgical Aortic Valve Replacement in Low-risk Patients with Aortic Stenosis

 

Authors: Baron SJ, Magnuson EA, Lu M, Wang K, et al.

Citation: J Am Coll Cardiol. 2019;74:2833–42
DOI:10.1016/j.jacc.2019.09.007.

Period of study: March 2016 and October 2019

Effective Operational Management in the Cardiac Catheterization Laboratory (Review paper)

 

Authors: Reed GW, Tushman ML, Kapadia SR.

Citation: J Am Coll Cardiol. 2018;72:2507–17
DOI:10.1016/j.jacc.2018.08.2179.

Period of study:

SCAI/ACVP expert consensus statement on cardiovascular catheterization laboratory economics

 

Authors: Blankenship JC, Choi JW, Das TS, McElgunn PM, et al.

Citation: Catheter Cardiovasc Interv. 2019; 94: 123–35
DOI:10.1002/ccd.28330.

Patient enrolment: May 2015 – October 2017

The cost-effectiveness of TAVR in low surgical risk patients with severe aortic stenosis

 

Authors: Tam DY, Azizi PM, Fremes SE, Chikwe J, et al.

Citation: Eur Heart J Qual Care Clin Outcomes. 2020 Jul 9;qcaa058. DOI: 10.1093/ehjqcco/qcaa058.

Period of study:

Summarising the evidence for improved patient outcomes and increased economic benefit with a TAVI procedure vs alternative pathways, taking into account organisational efficiency, budget considerations, patient choice and how to implement change in your organisation.

Management of severe symptomatic aortic stenosis in the age of COVID-19: A key paper summary

Read the key paper summary showing TAVI as the treatment of choice for all-risk ssAS patients carries even greater benefits during and post-COVID-19.

Improving care pathways: Permanent Pacemaker Insertion after TAVI

TAVI pathways need to be mapped out with PPI built into the patient journey with a consistent approach that optimises patient outcomes and service efficiency.

This content is sponsored by Edwards Lifesciences